We are live on
!
Find out more
ACM
Altium Capital Management Portfolio holdings
AUM
$47.5M
1-Year Est. Return
115.72%
This Fund
S&P 500
This Quarter
Est. Return
+12.22%
1 Year Est. Return
+115.72%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$360M
AUM Growth
+$92.4M
(+34%)
Cap. Flow
+$88.5M
Cap. Flow
% of AUM
24.56%
Top 10 Holdings %
Top 10 Hldgs %
19.65%
Holding
155
New
60
Increased
18
Reduced
21
Closed
31
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BIOR
Biora Therapeutics, Inc. Common Stock
BIOR
|
+$9.64M |
| 2 |
Rhythm Pharmaceuticals
RYTM
|
+$6.47M |
| 3 |
Aldeyra Therapeutics
ALDX
|
+$6.31M |
| 4 |
CareDx
CDNA
|
+$6.31M |
| 5 |
Verrica Pharmaceuticals
VRCA
|
+$6.28M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
IRD
Opus Genetics
IRD
|
+$15.5M |
| 2 |
Genprex
GNPX
|
+$6.81M |
| 3 |
AnaptysBio
ANAB
|
+$5.62M |
| 4 |
Cogent Biosciences
COGT
|
+$4.86M |
| 5 |
Celldex Therapeutics
CLDX
|
+$4.47M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 86.04% |
| 2 | Miscellaneous | 7.26% |
| 3 | Financials | 2.8% |
| 4 | Consumer Staples | 0.95% |
| 5 | Industrials | 0.89% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Curis
CRIS
$2.74M
| $8.74M | 2.43% |
1,930
-125
| -6% | -$523K |
|
|
2
Verrica Pharmaceuticals
VRCA
$84.3M
| $8.53M | 2.37% |
56,295
+45,416
| +417% | +$6.28M |
|
|
BIOR
3
DELISTED
Biora Therapeutics, Inc. Common Stock
BIOR
| $8.32M | 2.31% |
+6,993
| New | +$9.64M |
|
|
RCOR
4
DELISTED
Renovacor, Inc.
RCOR
| $7.57M | 2.1% |
753,374
+364,529
| +94% | +$3.77M |
|
|
EPIX
5
DELISTED
ESSA Pharma
EPIX
| $6.68M | 1.86% |
230,063
+54,996
| +31% | +$1.28M |
|
|
6
Aldeyra Therapeutics
ALDX
$80.8M
| $6.51M | 1.81% |
+548,225
| New | +$6.31M |
|
7
Verastem
VSTM
$663M
| $6.36M | 1.76% |
214,435
-13,230
| -6% | -$371K |
|
8
Protagonist Therapeutics
PTGX
$9.59B
| $6.17M | 1.71% |
238,354
+52,500
| +28% | +$1.33M |
|
|
BLU
9
DELISTED
BELLUS Health Inc.
BLU
| $6.04M | 1.68% |
1,573,389
-109,146
| -6% | -$414K |
|
10
Lantheus
LNTH
$6.55B
| $5.88M | 1.63% |
275,066
+12,601
| +5% | +$229K |
|
11
Syndax Pharmaceuticals
SNDX
$1.62B
| $5.67M | 1.57% |
253,448
-10,148
| -4% | -$229K |
|
|
ISEE
12
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $5.58M | 1.55% |
902,633
| – | – |
|
|
13
CareDx
CDNA
$2.6B
| $5.54M | 1.54% |
+81,284
| New | +$6.31M |
|
|
CRNX
14
DELISTED
Crinetics Pharmaceuticals
CRNX
| $5.53M | 1.54% |
361,930
| – | – |
|
15
Insulet
PODD
$9.15B
| $5.48M | 1.52% |
21,000
+4,800
| +30% | +$1.29M |
|
|
SIEN
16
DELISTED
Sientra, Inc.
SIEN
| $5.39M | 1.5% |
73,905
-1,358
| -2% | -$86.7K |
|
17
Ocular Therapeutix
OCUL
$2.3B
| $5.31M | 1.47% |
326,174
+23,000
| +8% | +$443K |
|
18
Aurinia Pharmaceuticals
AUPH
$2.14B
| $5.31M | 1.47% |
408,908
+114,991
| +39% | +$1.67M |
|
|
NVRO
19
DELISTED
NEVRO CORP.
NVRO
| $5.29M | 1.47% |
+37,900
| New | +$6.18M |
|
20
Travere Therapeutics
TVTX
$6.24B
| $5.26M | 1.46% |
210,484
+134,000
| +175% | +$3.7M |
|
21
Myriad Genetics
MYGN
$327M
| $5.23M | 1.45% |
171,785
-46,865
| -21% | -$1.33M |
|
22
Sutro Biopharma
STRO
$280M
| $5.16M | 1.43% |
22,672
-5,000
| -18% | -$1.19M |
|
|
MBTCU
23
DELISTED
Nocturne Acquisition Corporation Unit
MBTCU
| $5M | 1.39% |
+500,000
| New | +$5M |
|
24
Imunon
IMNN
$8.25M
| $4.83M | 1.34% |
+17,869
| New | +$6M |
|
|
25
Rhythm Pharmaceuticals
RYTM
$7.21B
| $4.74M | 1.32% |
+223,000
| New | +$6.47M |
|
Similar funds
BAM
VI
JCM
YEPX
OGC
MCM
BJB
NA
Altium Capital Management's Q1 2021 Portfolio in Review
As of Q1 2021, Altium Capital Management held 155 positions worth $360M, up 34% from $268M the previous quarter. Its ten largest holdings account for 20% of the portfolio.
Altium Capital Management deployed $88.5M of net new capital in Q1 2021, opening 60 new positions and adding to 18 existing holdings. Its largest new stake was Biora Therapeutics, Inc. Common Stock: 6,993 shares worth $8.32M.
By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 86% a quarter earlier, followed by Miscellaneous and Financials.
On the sell side, the largest reduction was Opus Genetics, an estimated $15.5M trimmed.
- Altium Capital Management's largest Q1 2021 buy was Biora Therapeutics, Inc. Common Stock: 6,993 shares worth $8.32M.
- Altium Capital Management added most to Verrica Pharmaceuticals in Q1 2021, an estimated $6.28M increase.
- Altium Capital Management's biggest Q1 2021 reduction was Opus Genetics, cutting an estimated $15.5M.
- Altium Capital Management fully exited AnaptysBio in Q1 2021, selling an estimated $5.62M.
- Altium Capital Management's ten largest holdings make up 20% of its $360M portfolio in Q1 2021.
- Altium Capital Management opened 60 new positions and closed 31 in Q1 2021.
- Altium Capital Management's portfolio value rose 34% quarter-over-quarter to $360M.
Based on Altium Capital Management's 13F filing for Q1 2021, filed 6 May 2021.